ORIENTBIO Signs Exclusive Primate CRO Business Rights Agreement with OrientCam

ORIENTBIO has signed an exclusive business rights agreement with its affiliate OrientCam to expand their non-clinical research (CRO) business for research-use primates.

According to ORIENTBIO on July 15, under this contract, ORIENTBIO will utilize the primate production facilities owned by OrientCam to exclusively conduct its CRO business targeting domestic and international pharmaceutical, biotech companies, and research institutions.

ORIENTBIO will oversee client contracts, the execution of non-clinical trials, quality assurance (QA), regulatory compliance, data analysis, and the development of an AI-based non-clinical platform. OrientCam will be responsible for the breeding and production of primates. The companies plan to establish an integrated AI non-clinical platform, linking stable primate supply to the execution of non-clinical studies and data analysis.

A company representative stated, "This contract will be an important milestone that connects the primate production infrastructure of the Orient Group with ORIENTBIO's expertise in non-clinical trials. We will strengthen cooperation with domestic and international pharmaceutical, biotech companies, and research institutions and actively pursue overseas expansion to enhance the competitiveness of our primate CRO business."

This content was produced with the assistance of AI translation services.